Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

Summary

This study is to provide idelalisib (IDELA) to individuals with relapsed, previously treated chronic lymphocytic leukemia (CLL) who have limited treatment options and are not eligible for other Gilead-sponsored studies.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications